Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

T-039

Supelco

Topiramate solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C12H21NO8S
Numéro CAS:
97240-79-4
Poids moléculaire :
339.36
Numéro CE :
200-659-6
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

1.0 mg/mL in methanol

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing

Format

single component solution

Température de stockage

−20°C

Chaîne SMILES 

CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1

InChI

1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1

Clé InChI

KJADKKWYZYXHBB-XBWDGYHZSA-N

Informations sur le gène

human ... CA2(760) , CA4(762) , GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879) , GRIA1(2890) , GRIA2(2891) , GRIA3(2892) , GRIA4(2893) , GRIK1(2897) , GRIK2(2898) , GRIK3(2899) , GRIK4(2900) , GRIK5(2901) , SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Description générale

A certified solution standard suitable for use in LC/MS or GC/MS applications for pharmaceutical research, clinical toxicology, or forensic testing.  Topiramate, sold under trade name Topamax®, is an antiepileptic drug used for treatment of seizures. Topiramate in combination with the stimulant phentermine constitute the active compounds in the new weight lose drug Qsymia®.

Application


  • Topiramate research solution: Research focuses on the development of intravenous formulations of topiramate for rapid intervention in seizure emergencies, highlighting its potential in emergency medicine and critical care (Epilepsy Behav, 2023; doi: 10.1016/j.yebeh.2023.109158).

  • Topiramate liquid formulation: Innovations in drug delivery include the use of topiramate-chitosan nanoparticles, which offer enhanced drug stability and targeted delivery, particularly in addiction treatment settings (Neurochem Int, 2021; doi: 10.1016/j.neuint.2021.105157).

  • Anticonvulsant biochemical reagent: Topiramate′s role as an anticonvulsant is further explored in studies focusing on its pharmacokinetic properties and interaction with other medications, emphasizing its importance in personalized medicine (Ther Drug Monit, 2019; doi: 10.1097/FTD.0000000000000600).

  • Topiramate in vitro study: The compound is utilized in in vitro setups to investigate its effects on neuronal excitability, providing insights into its mechanism of action and potential therapeutic applications (Epilepsia, 2019; doi: 10.1111/epi.16073).

  • Topiramate pharmacological research: Studies include the development of advanced analytical methods for the quantification of topiramate in biological samples, supporting its clinical monitoring and therapeutic drug management (J Pharm Biomed Anal, 2015; doi: 10.1016/j.jpba.2015.01.035).

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Qsymia is a registered trademark of Vivus, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Topamax is a registered trademark of Johnson & Johnson

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 2

1 of 2

Primidone analytical standard

Supelco

P7295

Primidone

Itraconazole ≥98% (HPLC)

Sigma-Aldrich

I6657

Itraconazole

J M Riffitts et al.
Journal of pharmaceutical and biomedical analysis, 19(3-4), 363-371 (2000-03-07)
An accurate and robust method involving liquid liquid extraction and capillary gas chromatographic (GC) assay with nitrogen phosphorus detection (NPD) was developed and validated for the quantitative determination of topiramate [2,3:4,5-bis-O-(-1-methylethylidene)-beta-D-fructopyranose sulfamate], Topamax, an anticonvulsant drug, in human plasma, urine
Elizabeth M Kelly et al.
Journal of managed care pharmacy : JMCP, 19(8), 642-654 (2013-10-01)
Obesity may lead to the development of multiple chronic disease states, including hypertension, dyslipidemia, and type 2 diabetes mellitus. Over a half billion adults worldwide are affected by obesity, and more than two-thirds of adults are either obese or overweight
Antonio Siniscalchi et al.
Pharmacological reports : PR, 64(1), 24-30 (2012-05-15)
Topiramate (TPM) is an O-alkyl sulfamate derivative of the naturally occurring monosaccharide D-fructose with an epileptic activity. However, it has been suggested that, in addition to its use in epilepsy, TPM could also be used in the treatment of neurological
Fernando Sierra-Hidalgo et al.
Clinical neuropharmacology, 36(2), 63-64 (2013-03-19)
Palinopsia is an illusory visual phenomenon consisting in the persistence or recurrence of visual images after the exciting stimulus object has been removed. It has been reported in association with parietal and occipital lobe lesions, migraine auras, and related to
Annie M Clark et al.
Epilepsia, 55(7), 1069-1076 (2014-05-28)
Evaluate the pharmacokinetics (PK), safety, and tolerability of single doses of once-daily USL255, Qudexy XR (topiramate) extended-release capsules, over a wide dosing range. Two single-dose, phase I studies in healthy adults were used to evaluate the PK profile and maximum
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique